Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
TAThe ACCORD Study Group and ACCORD Eye Study Group
Indexed incrossrefpubmed
Abstract
Background
We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy.
Methods
In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level,
Citation impact
1,293
total citations
- FWCI
- 101.24
- Percentile
- 100%
- References
- 36
Citations per year
Authors
1- TAThe ACCORD Study Group and ACCORD Eye Study GroupCorresponding
Topics & keywords
Topics
Keywords
- Medicine
- Glycemic
- Dyslipidemia
- Diabetic retinopathy
- Type 2 diabetes
- Retinopathy
- Diabetes mellitus
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ALAbbott Laboratories
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- RPRegeneron Pharmaceuticals
- MMMassachusetts Medical Society
- OHOmron Healthcare
- BHBayer HealthCare
- DDaiichi-Sankyo
- NNNovo Nordisk
- SServier
- NINational Institutes of Health
- CFCenters for Disease Control and Prevention
- NINational Institute on Aging
- NHNational Heart, Lung, and Blood InstituteAwards: N01-HC-95178, N01-HC-95184, IAA-Y1-HC-1010, N01-HC-95180, N01-HC-95183, IAA-Y1-HC-9035, N01-HC-95181, N01-HC-95179, N01-HC-95182
- NENational Eye Institute
- NINational Institute of Diabetes and Digestive and Kidney Diseases